Compare XMTR & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | VCEL |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2021 | 1996 |
| Metric | XMTR | VCEL |
|---|---|---|
| Price | $39.96 | $33.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $58.60 | $58.50 |
| AVG Volume (30 Days) | ★ 814.2K | 742.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.95 | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $686,631,000.00 | $276,259,000.00 |
| Revenue This Year | $23.76 | $19.10 |
| Revenue Next Year | $18.38 | $17.95 |
| P/E Ratio | ★ N/A | $104.91 |
| Revenue Growth | ★ 25.87 | 16.45 |
| 52 Week Low | $20.95 | $28.95 |
| 52 Week High | $73.87 | $45.97 |
| Indicator | XMTR | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 51.53 |
| Support Level | $39.50 | $31.24 |
| Resistance Level | $42.98 | $34.77 |
| Average True Range (ATR) | 2.59 | 1.66 |
| MACD | 0.67 | 0.39 |
| Stochastic Oscillator | 30.94 | 74.14 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.